IMPEDIMED LIMITED — Capital/Financing Update 2021

Jan 6, 2021

==> picture [230 x 54] intentionally omitted <==

7 January 2021

ASX ANNOUNCEMENT

Option Exercise and Preliminary Quarterly Cash Flow Results

Brisbane, Australia – ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health, today announced the results of the Option exercise for the December 2020 exercise date. In addition, based on the strong result from Option exercises, the Company has provided preliminary cash flow results for the quarter ending 31 December 2020.

Option Exercise for December 2020 Option exercise date

• $6.6 million in option exercise funds were received , compared to $1.1 million received for the June 2020 exercise date and $1.4 million received for the September 2020 exercise date.

• • As per the Appendix 2A report released this morning, 177,094,550 new shares were issued as a result of the exercise of options for the December 2020 exercise date.

March 2021 Option exercise date

• The final exercise date for the unlisted options ( Options ) issued under the 2 April 2020 Entitlement Offer is 31 March 2021.

• $9.1 million in Options remain outstanding and due this quarter.

• To participate, Option holders must exercise their outstanding Options prior to expiry at 5.00pm (Sydney time) on Wednesday, 31 March 2021.

• The outstanding Options are significantly in the money with an exercise price of $0.0375 compared to the latest available market price of IPD ordinary shares of $0.125.

• Further information pertaining to the exercise of outstanding Options will be forwarded to Option holders closer to the expiry date.

Preliminary Cashflow Results for the Quarter Ending 31 December 2020

• Net operating cash outflow is expected to be below $7.0 million for the six-month period ending 31 to December 2020 , significantly better than the forecasted $8.0 million net operating cash outflow announced to the market on 27 October 2020.

• The cash balance at 31 December 2020 was $19.0 million, including the December Option exercise funds.

• The Company has an additional $9.1 million in outstanding in-the-money Options due this quarter.

• Further details will be released in the Appendix 4C – Quarterly Cash Flow Report for the period ended 31 December 2020 on Thursday, 28 January 2021.

• The Company will conduct a conference call in conjunction with the release of the Appendix 4C – Quarterly Cashflow Report, with conference call details released closer to the date.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact: Mike Bassett, ImpediMed T: +61 407 431 432 E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Communications T: +61 3 8866 1200 E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.